The search terms were intended to capture concepts of "innovation" and "policy" in the health technology (drugs, devices, etc,) sector. Two researchers reviewed titles and abstracts of over 4500 references identifi ed; 200 papers were retrieved for full review. Key components of innovation were extracted and summarized in tabular form to identify trends and emerging themes. RESULTS: System disrupting, development of relationships and improvement on current practice are examples of components of, or criteria for defi ning, health technology innovation. Thematic concepts that emerged during the review include innovative health technology as a novelty and as a mechanism for achieving some benefi t or good (broadlydefi ned) at various levels of the health system. CONCLUSIONS: Based on the variety of defi nitions in the literature, lack of a common understanding of innovation may result in policy incoherence. The use of a consistent and unambiguous defi nition provides a solid framework from which to develop policy that is measurable, meaningful and, therefore, has a greater chance of being effective.
1 National School of Public Health, Athens, Greece; 2 Sotiria Hospital, Athens, Greece OBJECTIVES: Given the signifi cant impact of biomedical technology on health, the present study aims at identifying the accessibility to certain biomedical technologies and factors affecting its use and diffusion, in Greece. METHODS: A strictly structured questionnaire was designed and sent to a sample of 388 internists and GPs over 50 years old, stratifi ed by geographical area and employment sector. Participants were asked a) to evaluate on a 1 to 10 point scale patient access to selected biomedical technologies and the degree to which selected factors affect their decision to use the above interventions and b) to rank certain factors effect on the diffusion of biomedical technologies. RESULTS: The response rate was 76%. The statistical analysis revealed that the most accessible biomedical technologies were ultrasonography (9.4), PSA (9.38), cardiac enzymes (8.99), MRI and CT (8.86) , and mammography (8.83). The most important factors affecting participants' decision to use a technology were the treatment outcome (9.23), the disease severity (9.11) and the appropriateness of the technology for each condition (8.27) while factors such as health system and patient cost were proved less infl uential. 68.1% of participants claimed delays in the diffusion of biomedical technology in Greece, identifying as major barriers economic and specialized human resources defi ciencies. CONCLUSIONS: Based on our results, higher access was observed to technologies related to neoplasms and cardiovascular diseases, which represent the main causes of morbidity and mortality in Greece. Furthermore, our fi ndings support the view that when it comes to use a technology physicians are mostly concerned with the clinical effectiveness of an intervention and less with its impact on health care expenditures. Finally, the major diffusion barriers identifi ed in this study show a suboptimal resource allocation practice, stressing the need for measures to be taken in this direction in order to enhance diffusion of biomedical technologies in Greece.
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IMPLEMENTATION OF THE TRANSPARENCY DIRECTIVE IN HUNGARY
Kalo Z 1 , Nagyjanosi L 2 1 Eötvös Loránd University, Budapest, Hungary; 2 Syreon Research Institute, Budapest, Hungary OBJECTIVES: Transparency Directive (TD) of the European Union aims to ensure the transparency of procedures for the pricing and reimbursement of medicinal products by Member States. TD proposes strict timelines for the pricing and reimbursement process and indicates the necessity of objective and verifi able criteria for decisions and the availability of remedies for negative decisions. Our objective was to compare the routine process of pharmaceutical pricing and reimbursement with the TD in Hungary.
METHODS:
We analyzed offi cial resolutions of 29 pricing and reimbursement submissions by the National Health Insurance Fund (NHIF) between January and June 2008. In 14 cases the NHIF granted reimbursement, in 15 cases the reimbursement claim was rejected. We calculated the time period between the submission of the reimbursement dossier and the offi cial decision. We assessed the consistency of applying objective and verifi able criteria in positive or negative decisions. RESULTS: The average time period for pricing and reimbursement procedure was 172 days (min: 43 days; max: 534 days). We could not justify the consistency of employing objective and verifi able criteria in the pricing and reimbursement resolutions of innovative pharmaceuticals. CONCLUSIONS: The pharmaceutical pricing and reimbursement process in Hungary is neither transparent nor predictable. There are several open pricing and reimbursement submissions without resolution for long period. Although we could analyze only cases with resolution, the time period for pricing and reimbursment decision was still longer in several cases than 90 + 90 days recommended by TD. The appropriate use of scarce public health care resources could not be justifi ed in case of positive decisions and there is no remedy for negative reimbursement decisions. TD has been implemented only partially in Hungary.
PHP14 THE JOINT COMMITTEE FOR NEW DRUGS EVALUATION IN SPAIN: 6 YEARS OF EXPERIENCE Collar J
Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain OBJECTIVES: The Joint Committee for New Drugs Evaluation (JCNDE) was established in 2003 to improve effi ciency in drug evaluation in Spain. Five Regional Drug Evaluation Centres are part of it and have common Standard Operating Procedures (SOPs) which are regularly updated and improved. The objective of this study was to analyze the drugs innovation degree scores assigned by the JCNDE and timing between the new drug commercialization and the JCNDE evaluation. METHODS: The JCNDE SOPs defi ne a stepwise procedure with 4 key criteria for new drug innovation ratings: effi cacy, safety, convenience and drug cost. The drug innovation scores range from 0 (insuffi cient experience with the drug) to 4 (relevant therapeutic improvement). The drug evaluation results were gathered from JCNDE reports and from the Regional Drug evaluation centre reports. The time period analyzed was from 2004 to 2009. RESULTS: Ninety drug evaluations were held, considering 86 different drugs and 11 evaluations for a new drug indication for the same drug. Seventy-eight (87%) of the evaluations were negative (scores 0-1), not fi nding any 0 in the last 2 years of the study. Ten and 2 evaluations were scored as 2 and 3 respectively. None of the drugs assessed were considered a relevant therapeutic improvement compared to the existing options. Five drugs not reimbursed were evaluated. Median time since commercialization to evaluation was 6 months (IQR: 2-11 months) and 32 drug evaluations were held before up to a maximum of 3 months after commercialization. CONCLUSIONS: The JCNDE has been an effi cient instrument to develop new drug assessments in the Primary Care setting for the Regional Health Systems in Spain. Most of the assessments held have been negative. At present, health-economics arguments are basically focused on the daily treatment cost comparisons. About 1/3 of the evaluations are started before drug commercialization.
PHP15 DRUG COMPARATOR DIFFERENCES IN THE THERAPEUTIC BULLETINS IN SPAIN: THE JCNDE EXPERIENCE Collar J
Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain OBJECTIVES: The Spanish Joint Committee for New Drugs Evaluation (JCNDE) was created in 2003 and is formed by 5 Regional Drug Evaluation Centres. JCNDE has common Standard Operating Procedures (SOPs) to unify drug assessments and where the comparators availability is a key issue. Each individual Drug Evaluation Centre has its own new drug therapeutic bulletin to spread information between their health professionals. The objective of this study was to quantify the uniformity degree through the drug bulletins and the degree of heterogeneity refl ected in the drug costs. METHODS: New drug therapeutic bulletins of the 5 members of the JCNDE were reviewed between 2006 and 2009. Each drug assessed by the JCNDE was tracked to identify which members reported it in their bulletins. Comparative drugs included in the bulletins were also registered to fi nd potential heterogeneity amongst the JCNDE members. Daily/monthly treatment costs described were included in the study database. RESULTS: Fifty-seven drug evaluations were recorded, forty (70%) were published by at least 3 members of the JCNDE, and only 12 were published by all of them. Andalusia, Basque Country and Catalonia are the most active members, with 12-14 new drugs published per year. In all the bulletins were identifi ed some differences in the comparators used for each new drug assessed. Andalusia and Catalonia tend to include more comparators. The highest level of heterogeneity is observed in drugs of diabetes treatment. Most of the drug costs reported were very similar. Only one disagrement between the JCNDE was identifi ed in the drug innovation rating. CONCLUSIONS: JCNDE has made advances to unify drug assessment in Spain. Nevertheless, health-economics arguments are still focused on drug treatment cost comparisons. The comparators found in the drug bulletins are slightly different amongst the regions. Future SOPs version ought to improve these two weak points.
PHP17 ACCESSIBILITY TO ORPHAN DRUGS IN JAPAN-HAS THE ORPHAN DESIGNATION SYSTEM CONTRIBUTED?
Tomita N 1 , Kodama T 2 , Inagaki A 1 1 Keio University, Kanagawa, Japan; 2 National Institute of Public Health, Saitama, Japan OBJECTIVES: To promote the research and development of drugs for rare diseases, like other countries, orphan designations have been granted to pharmaceuticals in Japan since 1993. We investigated the accessibility of orphan drugs in Japan by comparing the accessibility of orphan designated and marketing authorised drugs in the EU and the US. METHODS: The present study used the data available until the November 30, 2009 from the European Medicines Agency, US Food and Drug Administration and National Institute of Biomedical Innovation. The International Nonproprietary Names (INNs) were used for comparing authorised orphan designated drugs in Japan, the EU and the US. RESULTS: A total of 228 products had been granted orphan designation, of which 142 (62%) obtained marketing authorization in Japan, which is equivalent to 122 in INNs. Meanwhile, the number of authorised orphan-designated medicines in INNs in the EU and the US was 57 and 198, respectively. Of the total 287 authorised orphan-designated pharmaceuticals in INNs in these 3 regions, 165 were inaccessible in Japan through the orphan designation system. Among such drugs, 25 (15%) were authorised orphan designated in both the EU and the US, 15 (9%) were authorised orphan designated in the EU alone and 125 (76%) were authorised orphan designated in the US alone. CONCLUSIONS: We
